A study evaluating treatment adherence in patients switching from deferasirox (DFX) dispersible tablet (DFX-DT) to film-coated tablet (DFX-FCT).

Trial Profile

A study evaluating treatment adherence in patients switching from deferasirox (DFX) dispersible tablet (DFX-DT) to film-coated tablet (DFX-FCT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Myelodysplastic syndromes; Sickle cell anaemia; Thalassaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 24 May 2017 Results (n=348) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 22 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top